{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:33:24Z","timestamp":1792402404135,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1053\/j.seminoncol.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T14:46:26Z","timestamp":1499957186000},"page":"132-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable"],"prefix":"10.1053","volume":"44","author":[{"given":"Vinay","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Kaestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.seminoncol.2017.06.007_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminoncol.2017.06.007_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminoncol.2017.06.007_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.007_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib5","article-title":"Pembrolizumab-ipilimumab combo is highly active in advanced melanoma","author":"London","year":"2016","journal-title":"Dermatology News"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib6","article-title":"Pembrolizumab plus ipilimumab safe, effective for advanced melanoma","author":"Kelsall","year":"2016","journal-title":"Perspective"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib7","first-page":"61","article-title":"Highlights of prescribing information: Opdivo","year":"2017","journal-title":"US Food and Drug Administration"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.06.007_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.06.007_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib10","article-title":"Emerging role of combination immunotherapy regimens in metastatic renal cell carcinoma","author":"McKay","year":"2016","journal-title":"ASCO Annual Meeting"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.06.007_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib12","first-page":"1","article-title":"Appraisal consultation document: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer","year":"2017","journal-title":"Excellence NIFHAC"},{"issue":"17","key":"10.1053\/j.seminoncol.2017.06.007_bib13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib14","article-title":"Nivolumab misses PFS endpoint in frontline phase III NSCLC study","author":"Inman","year":"2016","journal-title":"OncLive"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib15","author":"Bankhead","year":"2016","journal-title":"Nivolumab falls short in front-line NSCLC\u2014platinum chemotherapy prevails in randomized trial"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib16","article-title":"Few people actually benefit from \u2018breakthrough\u2019 cancer immunotherapy","author":"Gay","year":"2017","journal-title":"STAT"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.06.007_bib17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.007_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib19","article-title":"Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC) [Video]","year":"2016","journal-title":"ASCO University"},{"issue":"17","key":"10.1053\/j.seminoncol.2017.06.007_bib20","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1053\/j.seminoncol.2017.06.007_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1053\/j.seminoncol.2017.06.007_bib22","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.007_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"37","key":"10.1053\/j.seminoncol.2017.06.007_bib24","article-title":"With 20 agents, 803 trials, and 166,736 patient slots, is pharma investing too heavily in PD-1 drug development?","volume":"42","author":"Brawley","year":"2016","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.06.007_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8120106","article-title":"Advances in cancer immunotherapy in solid tumors","volume":"8","author":"Menon","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminoncol.2017.06.007_bib26","unstructured":"Drug Information. 2012. Available at: http:\/\/apps.who.int\/medicinedocs\/documents\/s19565en\/s19565en.pdf."},{"key":"10.1053\/j.seminoncol.2017.06.007_bib27","unstructured":"Assessment report: Opdivo. European Medicines Agency; April 23, 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/003985\/WC500189767.pdf."},{"key":"10.1053\/j.seminoncol.2017.06.007_bib28","unstructured":"Assessment Report: Keytruda. European Medicines Agency; May 21, 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR-Public_assessment_report\/human\/003820\/WC500190992.pdf."},{"key":"10.1053\/j.seminoncol.2017.06.007_bib29","article-title":"Division Director Summary Review: Pembrolizumab","author":"Keegan","year":"2014","journal-title":"Center for Drug Evaluation and Research"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T03:20:06Z","timestamp":1535599206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417300623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0093775417300623"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}